Board certified in Internal Medicine and Nephrology. Managing partner at Nephrology Associates, Chattanooga, for the past 5 years and has been with the organization since 1995. Manages an organization that includes 15 Nephrologists, with up to 23 physician extenders. Covers a 50 mile radius in the Southeast area of Tennessee with over 1,200 dialysis patients and 15,000 CKD patients. Has an MBA from the University of Tennessee at Chattanooga and actively participates in Clinical/Pharmaceutical Research at our research Organization: SERRI (Southeast Renal Research Institute). Medical Director for Network 8 (covers Mississippi, Alabama and Tennessee) as part of the Medicare Network Distribution.
The discussion will focus on highlighting the burden of Chronic Kidney Disease (CKD) and include the general principles for the management of patients with CKD. Identify ways to help delay progression of CKD. Will include the review of clinical trials focused on this and reducing proteinuria. Review recent data, particularly looking at trials involving SGLT-2 Inhibitors used in treatment of Type 2 Diabetes and their effect on CKD. Look at data on optimizing Blood Pressure control and the role of Ace-inhibitors and Angiotensin Blockers in patients with proteinuria. The second part of the discussion will attempt to initiate a discussion on the lack of quality clinical/therapeutic trials in Nephrology. Help bring about awareness of the need for not just more, but also the need for quality clinical and therapeutic interventions involving all aspects of Nephrology.